Cryo-Cell International (NYSEAMERICAN:CCEL) Posts Earnings Results

Cryo-Cell International (NYSEAMERICAN:CCEL) posted its quarterly earnings data on Friday. The company reported $0.16 earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $7.82 million for the quarter.

Cryo-Cell International Price Performance

NYSEAMERICAN:CCEL opened at $4.36 on Friday. The stock’s 50-day moving average is $4.05 and its two-hundred day moving average is $3.70. The stock has a market cap of $35.14 million, a PE ratio of -14.53 and a beta of 0.50. Cryo-Cell International has a fifty-two week low of $2.72 and a fifty-two week high of $4.90.

Institutional Investors Weigh In On Cryo-Cell International

A hedge fund recently raised its stake in Cryo-Cell International stock. Susquehanna International Group LLP increased its position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,064 shares of the company’s stock after buying an additional 4,046 shares during the period. Susquehanna International Group LLP owned 0.17% of Cryo-Cell International worth $45,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a biotechnology company that provides private stem cell banking and related biorepository services. The company collects, processes and cryogenically stores biological materials obtained primarily from umbilical cord blood and cord tissue, which may be preserved for potential future medical use by the donor or family members.

Its services generally include the coordination of collection kits and medical collection procedures, laboratory processing, testing and long-term storage.